Champions Oncology Inc. (CSBR) develops novel technologies for oncology diagnosis and treatment. It topped out at $23.88 in 2013 and entered a decline that posted an all-time low at $1.11 in August 2016. A basing pattern into November got bought, lifting the stock into a recovery wave that broke out above the 200-day EMA
in January 2017. It topped out and rolled over at the start of February, with the decline now positioned a few cents above moving average support. Look for committed buyers to take a stand here, ahead of a bounce that could new 2017 highs.